Eli Lilly to Acquire Ventyx Biosciences in Cash Deal

The latest update is out from Ventyx Biosciences ( (VTYX) ).

On January 7, 2026, Eli Lilly and Company agreed to acquire Ventyx Biosciences in an all-cash transaction valuing the target at about $1.2 billion, paying $14.00 per share of common stock and $1,400.00 per share of preferred stock, subject to customary conditions including shareholder and regulatory approvals. The deal, which carries a roughly 62% premium to Ventyx’s 30-day volume-weighted average share price and has already been approved by both companies’ boards, will make Ventyx a wholly owned subsidiary of Lilly, align its inflammation-focused pipeline with Lilly’s broader cardiometabolic, neurodegenerative and autoimmune franchise, and deliver cash consideration to equity holders under detailed provisions for stock, options and restricted stock units, while binding key insiders holding about 10% of the stock to support the transaction and establishing a $44 million termination fee to govern potential competing bids.

The most recent analyst rating on (VTYX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Ventyx Biosciences stock, see the VTYX Stock Forecast page.

Spark’s Take on VTYX Stock

According to Spark, TipRanks’ AI Analyst, VTYX is a Neutral.

The score is primarily held back by weak financial performance (pre-revenue, ongoing losses, and persistent negative free cash flow despite improvement). Technicals are supportive with the stock trading above major moving averages and positive MACD, while valuation remains constrained by negative earnings. A meaningful positive offset is the favorable Phase 2 clinical update for VTX3232.

To see Spark’s full report on VTYX stock, click here.

More about Ventyx Biosciences

Ventyx Biosciences is a San Diego-based, clinical-stage biopharmaceutical company specializing in innovative oral small-molecule therapies for inflammation-mediated diseases. Its pipeline centers on NLRP3 inhibitors such as VTX2735, in Phase 2 for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that has shown reductions in cardiovascular risk factors and completed a Phase 2 biomarker study in early-stage Parkinson’s disease, alongside Phase 2 candidates tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor for inflammatory bowel disease.

Average Trading Volume: 4,441,325

Technical Sentiment Signal: Buy

Current Market Cap: $558M

For a thorough assessment of VTYX stock, go to TipRanks’ Stock Analysis page.